Movement Disorders

Brain and Systemic Inflammation in De Novo Parkinson's Disease 2023

Rest and Digest—The Basal Role of Autophagy in Neurons and Its Relevance to Parkinson's Disease.  37:1806. 2022

Cortical and Subthalamic Nucleus Spectral Changes During Limb Movements in Parkinson's Disease Patients with and Without Dystonia.  37:1683-1692. 2022

Neuropsychological Functioning in Primary Dystonia: Updated and Expanded Multidomain Meta-Analysis.  37:1483-1494. 2022

John Q. Trojanowski, MD, PhD (1946-2022).  37:1123-1124. 2022

A Multi-center Genome-wide Association Study of Cervical Dystonia.  36:2795-2801. 2021

Potential PINK1 Founder Effect in Polynesia Causing Early-Onset Parkinson's Disease.  36:2199-2200. 2021

Inflammation in Experimental Models of α-Synucleinopathies.  36:37-49. 2021

Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease.  36:16-24. 2021

Progressive Supranuclear Palsy and Statin Use.  35:1253-1257. 2020

Reply to: Exercise for “Sleep Rehabilitation” in Parkinson's Disease.  35:1286. 2020

Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.  35:1055-1061. 2020

Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease.  35:947-958. 2020

Bridging the gaps: More inclusive research needed to fully understand Parkinson's disease.  35:231-234. 2020

Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?.  34:1406-1422. 2019

Utility and implications of exome sequencing in early-onset Parkinson's disease.  34:133-137. 2019

Glial GLP1R: A novel neuroprotector?.  33:1877. 2018

Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.  33:928-936. 2018

New Developments in Genetic rat models of Parkinson's Disease.  33:717-729. 2018

Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease.  33:793-804. 2018

Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.  33:468-472. 2018

Dysfunction in emotion processing underlies functional (psychogenic) dystonia.  33:136-145. 2018

Genetic influences on cognition in progressive supranuclear palsy.  32:1764-1771. 2017

Pedestrian safety in patients with Parkinson's disease: A case-control study.  32:1748-1755. 2017

What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease.  32:1341-1342. 2017

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.  32:1264-1310. 2017

Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.  32:1335-1336. 2017

The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.  32:1139-1146. 2017

Disparate genes come together: Spatial and genetic screens point to disruptions in vesicle trafficking and mRNA metabolism in synucleinopathies.  32:840. 2017

Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.  32:739-749. 2017

Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.  32:319-324. 2017

Cholinergic regulation of striatal dopamine release: New light in dark basements.  31:1796. 2016

Electromyographic evidence in support of a knock-in mouse model of DYT1 Dystonia.  31:1633-1639. 2016

Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.  31:1574-1577. 2016

SNPing SCNA regulatory elements gives a CRISPR view of genetic susceptibility in Parkinson's disease.  31:1479. 2016

Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.  31:1543-1550. 2016

Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis.  31:769-770. 2016

Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.  31:644-652. 2016

Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy.  31:742-747. 2016

Invisible Killers.  31:44-44. 2016

Study of plasma-derived miRNAs mimic differences in Huntington's disease brain.  30:1961-1964. 2015

Trophic factors for Parkinson's disease: To live or let die.  30:1715-1724. 2015

Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study.  30:1371-1381. 2015

Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel.  30:1435-1436. 2015

Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.  30:1222-1228. 2015

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.  30:919-927. 2015

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results.  30:500-509. 2015

Tourette syndrome deep brain stimulation: A review and updated recommendations.  30:448-471. 2015

The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.  30:278-283. 2015

Monocytes and Parkinson's disease: Invaders from outside?.  29:1242. 2014

Scientific perspectives.  29:1230. 2014

Effects of deep brain stimulation frequency on bradykinesia of Parkinson's disease.  29:203-206. 2014

Reaping what you sow: Cross-seeding between aggregation-prone proteins in neurodegeneration.  29:306-306. 2014

Metabolomics and the search for biomarkers in Parkinson's disease.  28:1620-1621. 2013

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.  28:1675-1682. 2013

Lysosomal impairment in Parkinson's disease.  28:725-732. 2013

Measuring mild cognitive impairment in patients with Parkinson's disease.  28:626-633. 2013

Which dyskinesia scale best detects treatment response?.  28:341-346. 2013

Multisite, double-blind, randomized, controlled study of pregabalin for essential tremor.  28:249-250. 2013

Design innovations and baseline findings in a long-term parkinson’s trial: The national institute of neurological disorders and stroke exploratory trials in parkinson’s disease long-term study-1.  27:1513-1521. 2012

Reliability of a new scale for essential tremor.  27:1567-1569. 2012

Short latency activation of cortex by clinically effective thalamic brain stimulation for tremor.  27:1404-1412. 2012

Short latency activation of cortex during clinically effective subthalamic deep brain stimulation for Parkinson's disease.  27:864-873. 2012

High-frequency deep brain stimulation of the putamen improves bradykinesia in Parkinson's disease.  27:168-169. 2012

Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.  26:2190-2195. 2011

High-frequency deep brain stimulation of the putamen improves bradykinesia in Parkinson's disease.  26:2232-2238. 2011

Genomewide linkage study of modifiers of LRRK2-related Parkinson's disease.  26:2039-2044. 2011

Parkinson's disease, primates, and gene therapy: Vive la différence?.  26:2-3. 2011

Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.  25:2156-2163. 2010

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.  25:858-866. 2010

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.  24:564-573. 2009

Medical decision-making capacity in cognitively impaired Parkinson's disease patients without dementia.  23:1867-1874. 2008

Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease..  23:1830-1836. 2008

Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD study.  23:1596-1601. 2008

Adult-onset Alexander disease with progressive ataxia and palatal tremor.  23:118-122. 2008

Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.  23:88-95. 2008

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.  22:2409-2417. 2007

R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation.  22:254-256. 2007

Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine.  22:99-104. 2007

Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families.  22:55-61. 2007

Report from a U.S. conference on essential tremor.  21:2052-2061. 2006

Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinics.  21:519-523. 2006

Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study.  20:1188-1191. 2005

Apolipoprotein E ε4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: Relationship to dementia and hallucinations.  20:989-994. 2005

Escaping Parkinson's disease: A neurologically healthy octogenarian with the LRRK2 G2019S mutation [2].  20:1077-1078. 2005

Association between male gender and pediatric essential tremor.  20:904-906. 2005

Atypical Hallervorden-Spatz disease with preserved cognition and obtrusive obsessions and compulsions.  20:880-886. 2005

Interrater agreement in the assessment of motor manifestations of Huntington's disease.  20:293-297. 2005

Dominantly-inherited adult-onset leukodystrophy with palatal tremor caused by a mutation in the glial fibrillary acidic protein gene.  19:1244-1248. 2004

Clinical signs and symptoms in a large hereditary spastic paraparesis pedigree with a novel spastin mutation.  19:641-648. 2004

Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2).  19:622-629. 2004

SCA2 may present as levodopa-responsive parkinsonism.  18:425-429. 2003

Molecular diagnosis of unherited movement disorders. Movement disorders society task force on molecular diagnosis.  18:3-18. 2003

Essential tremor in childhood: A series of nineteen cases.  16:921-923. 2001

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.  16:858-866. 2001

Research goals in progressive supranuclear palsy.  15:446-458. 2000

Research goals in progressive supranuclear palsy.  15:446-458. 2000

Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease.  14:590-595. 1999

Paroxysmal dyskinesia in a patient with pseudohypoparathyroidism.  13:746-748. 1998

Bobble-head doll syndrome: report of a case and review of the literature..  12:810-814. 1997

Erratum: Malondialdehyde immunohistochemistry in Parkinson's disease (Movement Disorders (1996) 11 (592)).  12:131. 1997

Evidence of cortical metabolic dysfunction in early Huntington's disease by single -photon-emission computed tomography.  11:671-677. 1996

Event-related potential P3 change in mild Parkinson's disease.  11:32-42. 1996

The Bereitschaftspotential preceding stepping in patients with isolated gait ignition failure.  10:18-21. 1995

The syndrome of gait ignition failure: A report of six cases.  8:285-292. 1993

Core assessment program for intracerebral transplantations (CAPIT).  7:2-13. 1992

Rett syndrome and associated movement disorders.  5:195-202. 1990

Waht is it? Case 1, 1990: Progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb.  5:341-351. 1990